Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Second-Line Therapies for Patients With mCRC

April 2nd 2013

Determining Optimal Treatments in mCRC

April 2nd 2013

Treatment Sequencing in Metastatic Colorectal Cancer

April 2nd 2013

Treating Unresectable Metastatic Colorectal Cancer

April 2nd 2013

Treating Resectable Metastatic Colorectal Cancer

April 2nd 2013

Exploring the Neoadjuvant Treatment of Rectal Cancer

April 2nd 2013

Understanding the Role of Aspirin in Colorectal Cancer

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part II

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part I

April 2nd 2013

Side Effects With Regorafenib Occur Early and Tend to Taper

March 8th 2013

The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.

Bevacizumab Plus FOLFOXIRI May Offer New First-Line Option in mCRC

March 5th 2013

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Dr. Bendell on Hsp90 Inhibition in Advanced Solid Tumors

March 4th 2013

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Dr. Grothey on Bevacizumab Beyond Progression in mCRC

February 22nd 2013

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.

Dr. Kim on Administering Aflibercept in mCRC

February 19th 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

Colorectal Surgery

February 19th 2013

A consensus panel issues a set of discharge warning instructions regarding colorectal surgery.

Dr. Grothey Examines Adjuvant Oxaliplatin in Colon Cancer

February 7th 2013

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses a survey that examined the perceived benefits and use of adjuvant oxaliplatin in colon cancer.

Dr. Ruff Analyzes Overall Survival in the VELOUR Trial

February 1st 2013

Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.

Dr. Kim on the Investigation of Regorafenib in mCRC

January 31st 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

Extended Survival Benefit With Zaltrap Seen in Metastatic Colorectal Cancer

January 28th 2013

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.

Dr. Grothey on the Time Course of Regorafenib-Associated AEs

January 28th 2013

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.